A new analysis in the British Journal of Cancer suggests the timing of immune checkpoint inhibitor dosing can influence overall survival in advanced cancer. Instead of focusing only on whether immunotherapy works, the study evaluates how when therapy is administered relates to patient outcomes. The research draws on a large, single-centre cohort and looks specifically at treatment timing as a potential driver of survival differences. That framing may help clinicians reconsider scheduling and sequencing questions when designing immunotherapy regimens. While the results are observational, the study adds to growing interest in real-world optimization of immunotherapy beyond selecting a drug and moving directly to response endpoints.